Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.

IF 1.8 Q2 OTORHINOLARYNGOLOGY
OTO Open Pub Date : 2024-10-26 eCollection Date: 2024-10-01 DOI:10.1002/oto2.70040
Elena Kennedy, Greg Durm, Janice L Farlow
{"title":"Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.","authors":"Elena Kennedy, Greg Durm, Janice L Farlow","doi":"10.1002/oto2.70040","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To provide a review of the science and applicability of current multi-cancer early detection (MCED) tests for otolaryngologists.</p><p><strong>Data sources: </strong>PubMed, clinicaltrials.gov, company websites.</p><p><strong>Review methods: </strong>Using PRISMA methodology, primary literature regarding MCED tests was queried from April 26 to May 12, 2024 using MCED search terms. Ongoing clinical trials incorporating MCED screens were identified via the National Institutes of Health clinicaltrials.gov website. Company websites for available or upcoming MCED tests were reviewed.</p><p><strong>Conclusion: </strong>Long-term robust data regarding the performance characteristics, effects on clinical outcomes, and cost-utility of MCED tests for head and neck cancer are currently lacking. Otolaryngologists should be aware of the implications of MCED tests as these assays become more widely used.</p><p><strong>Implications for practice: </strong>Although not FDA-approved or covered by insurances at the time of writing of this manuscript, MCED testing is rapidly gaining interest, and patients with positive tests are presenting to otolaryngologists for evaluation. While MCED technologies hold great promise for early detection of disease and potential reduction of morbidity and mortality, more study is needed about their utility for head and neck cancer and optimal diagnostic workflows.</p>","PeriodicalId":19697,"journal":{"name":"OTO Open","volume":"8 4","pages":"e70040"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512445/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OTO Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/oto2.70040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To provide a review of the science and applicability of current multi-cancer early detection (MCED) tests for otolaryngologists.

Data sources: PubMed, clinicaltrials.gov, company websites.

Review methods: Using PRISMA methodology, primary literature regarding MCED tests was queried from April 26 to May 12, 2024 using MCED search terms. Ongoing clinical trials incorporating MCED screens were identified via the National Institutes of Health clinicaltrials.gov website. Company websites for available or upcoming MCED tests were reviewed.

Conclusion: Long-term robust data regarding the performance characteristics, effects on clinical outcomes, and cost-utility of MCED tests for head and neck cancer are currently lacking. Otolaryngologists should be aware of the implications of MCED tests as these assays become more widely used.

Implications for practice: Although not FDA-approved or covered by insurances at the time of writing of this manuscript, MCED testing is rapidly gaining interest, and patients with positive tests are presenting to otolaryngologists for evaluation. While MCED technologies hold great promise for early detection of disease and potential reduction of morbidity and mortality, more study is needed about their utility for head and neck cancer and optimal diagnostic workflows.

多癌早期检测试验:耳鼻喉科医生的最新研究综述。
目的:为耳鼻喉科医生提供当前多癌早期检测(MCED)的科学性和适用性综述:数据来源:PubMed、clinicaltrials.gov、公司网站:采用PRISMA方法,使用MCED检索词查询了2024年4月26日至5月12日有关MCED检测的主要文献。通过美国国立卫生研究院 clinicaltrials.gov 网站确定了纳入 MCED 筛选的进行中临床试验。对现有或即将进行 MCED 试验的公司网站进行了审查:目前尚缺乏有关头颈部癌症 MCED 检测的性能特征、对临床结果的影响以及成本效益的长期可靠数据。随着MCED检测的广泛应用,耳鼻喉科医生应了解这些检测的影响:尽管在撰写本手稿时,MCED 检测尚未获得美国食品及药物管理局的批准,也未被纳入保险范围,但它正迅速引起人们的兴趣,检测呈阳性的患者正在向耳鼻喉科医生求诊。尽管MCED技术在早期发现疾病、降低发病率和死亡率方面大有可为,但仍需对其在头颈部癌症中的应用以及最佳诊断流程进行更多研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
OTO Open
OTO Open Medicine-Surgery
CiteScore
2.70
自引率
0.00%
发文量
115
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信